Labcorp Holdings Inc.

Valuation Analysis

About the Company

Labcorp Holdings Inc. en bref

Labcorp Holdings Inc. (LH) is currently trading at 223,06 € with a market capitalization of 18,3 Md €. The trailing P/E ratio stands at 22.68x, with a forward P/E of 13.16x. The 52-week range spans from 210,80 € to 256,05 €; the current price is 12.9% below the yearly high. Year-over-year revenue growth stands at +5.8%. The net profit margin stands at 6.66%.

💰 Dividende

Labcorp Holdings Inc. pays an annual dividend of 2,51 € per share, representing a yield of 1.13%. The payout ratio stands at 25.51%.

📊 Avis des analystes

17 analystes évaluent Labcorp Holdings Inc. (LH) au consensus : Acheter. L'objectif de cours moyen est de 270,35 €, soit un potentiel de +21.2% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 235,38 € à 296,40 €.

Labcorp Holdings Inc. : la thèse d'investissement en détail

Labcorp Holdings Inc. (LH) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 32.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 21.2% upside from current levels — analyst sentiment is firmly constructive.

Valorisation en contexte

The PEG ratio at 1.12 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 13.16x is meaningfully below the trailing 22.68x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 21.2% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Labcorp Holdings Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.